ArticleProceedings of the National Academy of Sciences of the United States of America1994
Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.Pharmacology & therapeutics · 2020Pooled it
- Safety evaluation of a new anxiolytic product containing botanicalsCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2018Trial
- Molecular Diversity of Lupane Hybrids in Drug Design and Materials Science.Molecules (Basel, Switzerland) · 2025Review
- Facial Synthesis and Bioevaluation of Well-Defined OEGylated Betulinic Acid-Cyclodextrin Conjugates for Inhibition of Influenza Infection.Molecules (Basel, Switzerland) · 2022Article
- A Review on Preparation of Betulinic Acid and Its Biological Activities.Molecules (Basel, Switzerland) · 2021Review
- Evaluation of A-azepano-triterpenoids and related derivatives as antimicrobial and antiviral agents.The Journal of antibiotics · 2021Article
- Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.Molecules (Basel, Switzerland) · 2021Article
- Recent advances in natural anti-HIV triterpenoids and analogs.Medicinal research reviews · 2020Review
- New Phosphorus Analogs of Bevirimat: Synthesis, Evaluation of Anti-HIV-1 Activity and Molecular Docking Study.International journal of molecular sciences · 2019Article
- Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes.Science advances · 2018Article
- Structure and Anti-HIV Activity of Betulinic Acid Analogues.Current medical science · 2018Review
- Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives.Medicinal research reviews · 2018Review
- Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).Frontiers in pharmacology · 2018Article
- Poly(lactic-International journal of nanomedicine · 2018Article
- Evaluation of the cytotoxic potential of a new pentacyclic triterpene from Rhododendron arboreum stem bark.Pharmaceutical biology · 2017Article
- Hyaluronidase Inhibitory Activity of Pentacylic Triterpenoids from Prismatomeris tetrandra (Roxb.) K. Schum: Isolation, Synthesis and QSAR Study.International journal of molecular sciences · 2016Article
- Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.Bioorganic & medicinal chemistry letters · 2015Article
- New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.Journal of medicinal chemistry · 2013Article
- Review
- Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of triterpene compounds characterized by a stringent structure-activity relationship were identified as potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Currently studied botulinic derivatives have 50% inhibitory concentrations (IC50) against HIV-1 strain IIIB/LAI in the 10 nM range in several cellular infection assays but are inactive against HIV-2. These compounds did not significantly inhibit the in vitro activities of several purified HIV-1 enzymes. Rather, they appeared to block virus infection at a postbinding, envelope-dependent step involved in the fusion of the virus to the cell membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.